Key Highlights
- Verici Dx Plc (LSE:VRCI) shares climbed 7.14% on 1 October 2026, one of the strongest gains among London small caps on a weak day for the wider market.
- Half-year results showed Tutivia test Revenue up 53% year on year to $1.77 million.
- 35 US transplant centres are now using Tutivia, with three added since 30 June.
- Average reimbursement is running at around $2,300 per test, and a new in-network agreement with Blue Cross and Blue Shield of Illinois widens patient access.
- A second product, the TranscripTx transplant genetic test, is lined up for launch in the fourth quarter of 2026.
Why Verici Dx Is in Focus Today
Verici Dx Plc (LSE:VRCI), the precision diagnostics company focused on kidney transplant care, was firmly on investor radar on 1 October 2026 as its shares advanced 7.14%. The gain stood out on a day when the FTSE 100 fell more than 1% as UK long-dated gilt yields neared a three-decade high.
The trigger was the company's half-year results for the six months to 30 June 2026, published late on 30 September, which gave the market its first full read on how quickly the Tutivia test is scaling now that reimbursement is firmly in place.
Tutivia Revenue Up 53% Drives the Rally
The headline number investors seized on was Tutivia test revenue, which rose 53% compared with the same period last year to $1.77 million. Tutivia is a blood-based transcriptomic test designed to detect the risk of acute rejection after a kidney transplant, helping clinicians distinguish true rejection from other causes of graft injury.
Total reported revenue was lower than the first half of 2025, but that comparison is distorted. The prior-year figure of $1.9 million included a one-off $0.75 million licensing milestone from Thermo Fisher Scientific linked to the PTRA assay. Stripping that out, the underlying commercial engine of the business, test sales, is growing at a healthy pace, and that is what the market chose to reward.
Network Expansion to 35 Transplant Centres
Verici Dx reported that 32 transplant centres were onboarded and ordering during the first half, with three more added since 30 June. That brings the total to 35 US centres using Tutivia. Earlier in the year, the company said its adopting centres represented about one fifth of annual US kidney transplants, and the network has continued to widen since then.
Adoption in transplant medicine tends to be sticky, as centres that embed a test into protocols usually reorder. In the first quarter the company reported 392 Tutivia tests, up 32% on the prior quarter.
Reimbursement Momentum Strengthens the Investment Case
For a small diagnostics company, getting paid is just as important as getting orders. Verici Dx said it is currently achieving an average reimbursement rate of about $2,300 per test. Tutivia is already covered by Medicare at a national rate of $2,650, and coverage has been extended to 17 state Medicaid programmes.
The company has also signed an agreement with Blue Cross and Blue Shield of Illinois, giving insured patients in-network status for Tutivia. This follows an earlier provider participation agreement with Prime Health Services, one of the largest preferred provider organisations in the US. In addition, New York State laboratory accreditation earlier this year means Verici Dx can now provide testing in all 50 US states and the District of Columbia.
TranscripTx Launch Adds a Second Revenue Stream
Investors are also watching the planned fourth-quarter 2026 launch of TranscripTx, a transplant genetic test that will be offered from the company's CLIA-certified, CAP-accredited US laboratory. The product is designed to extract additional value from the clinical data and samples Verici Dx has built up, and it broadens the company's offering beyond its lead test.
The wider portfolio also includes Clarava for pre-transplant risk and Protega for progressive fibrosis.
What Investors Are Watching Next
Verici Dx remains a very small company with a sub-penny share price, so Volatility is high. The shares fell heavily in 2025 after a revenue downgrade, and the Business has relied on Equity fundraising. Cash runway, the pace of quarterly test volumes and further payer agreements will remain the key swing factors.
Clinical evidence also matters, and new predictive data on Tutivia was presented at the American Transplant Congress in June 2026.
For now, the half-year numbers suggest that the combination of rising test volumes, improving reimbursement and a growing centre network is beginning to show up in the revenue line, which explains why Verici Dx Plc (LSE:VRCI) was among the standout risers on 1 October 2026.






Please wait processing your request...